Biotech Values

[vinmantoo]

MRNA projects 2H22 boost in vaccine sales:

That is also potentially good news for NVAX. It surged over ~30% since last week in the news the FDA advisory committee will meet on June 7th to decide on whether to approve their protein-based Covid vaccine. NVAX earnings come out Monday May 9th so that will likely affect the price one way or another. I am still down ~30% but may decide to nibble a bit more. The NVAX vaccine is approved in the EU and many non-EU countries including India, and while sales there were initially slow it is finally ramping up. Approval in the US should spike the price dramatically. Of course, if the FDA rejects or delays.....